Navigation Links
Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute
Date:8/26/2008

- Results in Proceeds of $2.0 Million -

MONTVALE, N.J., Aug. 26 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today announced that it has secured $2.0 million through the sale of approximately 4.7 million shares of common stock at $0.42 per share under its June 2007 equity financing agreement with an investment group led by The Stanley Medical Research Institute (SMRI). Memory Pharmaceuticals exercised its option to complete the third and final tranche following the achievement of a predefined milestone related to the Phase 2a trial of R3487/MEM 3454 in cognitive impairment associated with schizophrenia (CIAS). Under the terms of the financing agreement, the shares were priced at a 17% premium to the average closing sale price of the Company's common stock for the ten days ending on the day of the Company's achievement of the specified milestone.

"We appreciate SMRI's long-standing support for this program and we are pleased that we have once again been able to translate our progress into an opportunity to raise capital at a premium," stated Vaughn M. Kailian, President and Chief Executive Officer of Memory Pharmaceuticals. "Cognitive impairment is a major component of schizophrenia that contributes to a patient's dysfunction, and our ongoing Phase 2a trial will provide us with important insights on R3487/MEM 3454's potential efficacy in this indication."

In June 2007, Memory entered into an equity financing agreement with the investment group led by SMRI for the sale of up to $6.0 million of common stock in three tranches. The Company closed the first $2.0 million tranche in June 2007, and exercised its option to secure an additional $2.0 million in a second tranche in June 2008. With today's
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
2. New kind of MRI enables study of magnets for computer memory
3. Memory Pharmaceuticals Receives Anticipated NASDAQ Staff Determination Letter
4. Memory Pharmaceuticals Reports First Quarter 2008 Financial Results
5. Memory Pharmaceuticals to Announce First Quarter 2008 Results on Wednesday, May 14, 2008
6. Memory in artificial atoms
7. Memory Pharmaceuticals Receives Nasdaq Notification
8. Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification
9. Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
10. Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008
11. Memory Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... 2014 In recent years, growing suspicion ... in product development and promotion has led to unprecedented ... fueled by concerns about the insidious impact of commercialization ... spectacular fines to the world’s biggest pharmas for illegal ...
(Date:1/14/2014)... UK (PRWEB) January 13, 2014 Bob ... with more than 20 years in the industry, has ... photonics . Hainsey will serve as the society’s Science ... Dr. Hainsey join SPIE as our Technology Strategist, further ...
(Date:1/14/2014)... BioMedomics, Inc. , a Point of Care ... novel disease specific POC tests, announced today that it has ... of $690,000. The investment is from private investors and is ... of private investors has significant successful experience in early investments ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2BioMedomics, Inc. Closes $690K Round of Financing 2
... The " Anesthesia Drugs Market (2011 ... studies the U.S. market for intravenous anesthesia drugs with special focus on ... import system for controlled substances in U.S. and U.S. market entry strategy. ...   " Anesthesia Drugs Market (2011 - ...
... was able to reach for and sip from a drink on ... by using her thoughts to direct a robotic arm. ... is evaluating the safety and feasibility of an investigational device called ... brain-computer interface (BCI) intended to put robotics and other assistive technology ...
...  Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR ) announced ... Company,s common share repurchase program authorization by an additional ... 2008, the Company has returned $236 million to shareholders ... preferred shares, representing approximately 27% of its shares as ...
Cached Biology Technology:Anesthesia Drugs Market in U.S. worth $7 Billion by 2015: MarketsandMarkets 2Anesthesia Drugs Market in U.S. worth $7 Billion by 2015: MarketsandMarkets 3Paralyzed individuals use thought-controlled robotic arm to reach and grasp 2Paralyzed individuals use thought-controlled robotic arm to reach and grasp 3Paralyzed individuals use thought-controlled robotic arm to reach and grasp 4Paralyzed individuals use thought-controlled robotic arm to reach and grasp 5Questcor Pharmaceuticals Expands Repurchase Program 2Questcor Pharmaceuticals Expands Repurchase Program 3Questcor Pharmaceuticals Expands Repurchase Program 4Questcor Pharmaceuticals Expands Repurchase Program 5
(Date:4/20/2014)... breast and pancreatic cancers also promote drug-resistance and ultimately ... San Diego School of Medicine have discovered a molecule, ... tumors that appears responsible for inducing tumor metastasis by ... , The findings, published in the April 20, 2014 ... point to new therapeutic opportunities for reversing drug resistance ...
(Date:4/20/2014)... -- Using corn crop residue to make ethanol and ... greenhouse gases than gasoline, according to a study published ... , The findings by a University of Nebraska-Lincoln team ... be used to meet federal mandates to ramp up ... stover -- the stalks, leaves and cobs in cornfields ...
(Date:4/18/2014)... population predicted to reach 9 billion by 2050 ... considers human-altered landscapes such as farmland, according to ... that supports it might be an increasingly scarce ... of the land surface is directly affected by ... impacts such as climate change. But what if ...
Breaking Biology News(10 mins):Cancer stem cells linked to drug resistance 2Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4
... of biodiversity, but there has been no effective way ... areas. As a result, we have limited understanding of ... are affecting these delicate ecosystems. A major advance in ... Asner of the Carnegie Institution,s Department of Global Ecology ...
... 2008) With the sequencing of the human genome ... a genes and other DNA sequences can vary widely between ... our species, genetic diversity but it has also been linked ... Harbor Protocols ( www.cshprotocols.org/TOCs/toc6_08.dtl ) features a new method ...
... the human malaria parasite, Plasmodium falciparum, which is responsible ... from becoming sexually mature. The discovery ... resistance, which is a major public health problem and ... cycle of Plasmodium falciparum is complex, and it is ...
Cached Biology News:Revolution in rain forest monitoring with MacArthur grant 2Cold Spring Harbor Protocols features methods for analyzing genomes and plant cells 2
... are designed to rapidly and reliably ... our patented APA Technology. APAgene provides ... extraordinarily competitive price. All necessary ingredients ... Locator Kit can be used for ...
... Linkage: This CLS number ... created to easily match Cornings ... availability yet, please order under ... or contact customer service for ...
... system automates the denaturation and hybridization steps ... convenience for clinical and research personnel. The ... of sample types, is easy to use, ... 50% while ensuring overall precision and accuracy ...
... Buffer is a convenient, premixed, ... samples and Perfect RNA Markers. ... no dilution and is suitable ... Simply mix equal volumes of ...
Biology Products: